CN-122005708-A - Application of bispermatid in preparing medicine for treating hyperhomocysteinemia-derived atherosclerosis

Abstract

The invention provides an application of a bispermatid in preparing a medicine for treating hyperhomocysteinemia-derived atherosclerosis, relates to the technical field of application of the bispermatid, has the unique advantages of multiple targets, multiple ways and low toxic and side effects, is a safe and effective medicine without adverse reaction, has remarkable effects in the aspects of regulating Hcy metabolism, improving vascular endothelial functions, stabilizing arterial plaques and the like, and can improve the foaming of macrophages and VSMCs by regulating lipid accumulation, inhibiting inflammatory reaction, relieving oxidative stress injury, thereby playing a role in relieving HHHcy-derived atherosclerosis.

Inventors

• ZHANG LIMING
• LI HANGYING
• YE MINGXING
• ZHAO CAIPING
• ZHANG YUANYUAN

Assignees

• 宁夏医科大学

Dates

Publication Date

20260512

Application Date

20260303

Claims (6)

1. 1. An application of a bispermatid in preparing medicine for treating hyperhomocysteinemia-derived atherosclerosis.
2. 2. Use of a bijective according to claim 1 for the preparation of a medicament for the treatment of hyperhomocysteinemia-derived atherosclerosis, wherein the bijective reduces homocysteine levels in serum.
3. 3. The use of a bijective according to claim 2 for the preparation of a medicament for the treatment of hyperhomocysteinemia-derived atherosclerosis, wherein said bijective is capable of exerting an anti-atherosclerosis effect by modulating lipid, reducing oxidative stress, inhibiting inflammatory response.
4. 4. The use of a bijective according to claim 1 for the preparation of a medicament for the treatment of hyperhomocysteinemia-derived atherosclerosis, wherein said bijective is capable of improving macrophage and vascular smooth muscle cell foaming.
5. 5. The use of a bijective according to claim 1 for the preparation of a medicament for the treatment of hyperhomocysteinemia-derived atherosclerosis, wherein the bijective is used in an amount of 1.4g/kg to 5.6g/kg.
6. 6. Use of a composition containing a bispermatid in the preparation of a medicament for the treatment of hyperhomocysteinemia-derived atherosclerosis.

Description

Application of bispermatid in preparing medicine for treating hyperhomocysteinemia-derived atherosclerosis Technical Field The invention belongs to the technical field of application of a bijing prescription, and particularly relates to application of the bijing prescription in preparation of a medicine for treating hyperhomocysteinemia-induced atherosclerosis. Background Atherosclerosis (AS) is a chronic inflammatory vascular disease, is a core pathological basis of cardiovascular and cerebrovascular events such AS coronary heart disease, cerebral infarction and the like, and has high morbidity and mortality in the global scope, thereby seriously threatening the health of human beings. With the penetration of clinical studies, hyperhomocysteinemia (Hyperhomocysteinemia, HHcy) has been shown to be an independent risk factor for the development of AS. When homocysteine (Homocysteine, hcy) level in blood exceeds 15 mu mol/L, the formation and instability of atherosclerosis plaque can be accelerated by various ways of damaging vascular endothelial function, promoting lipid peroxidation, inducing inflammatory reaction, oxidative stress and the like, and the incidence risk of cardiovascular and cerebrovascular diseases is obviously increased. At present, clinical intervention aiming at Hhcy mainly uses folic acid supplementation and statin drugs as main drugs, and although Hcy level can be reduced to a certain extent and blood fat can be regulated, adverse reactions such as liver injury, muscle pain and the like are easy to cause after long-term use. Therefore, a safe, effective and untoward-effect-free drug for treating hyperhomocysteinemia-derived atherosclerosis needs to be explored. Disclosure of Invention In view of the above, the present invention provides a safe, effective and untoward effect-free medicament for treating hyperhomocysteinemia-derived atherosclerosis. An application of a bispermatid in preparing medicine for treating hyperhomocysteinemia-derived atherosclerosis. Preferably, the bivariate reduces homocysteine levels in serum. Preferably, the bijective formulation is capable of exerting an anti-atherosclerosis effect by modulating lipid, reducing oxidative stress, and inhibiting inflammatory response. Preferably, the bijective is capable of improving macrophage and vascular smooth muscle cell foaming. Preferably, the bispermatid plays an anti-atherosclerosis role by regulating lipid, and particularly can improve the stability of aortic atherosclerotic plaques and reduce the TC and TG levels in blood lipid. Preferably, the bispermatid exerts an anti-fibrotic effect by inhibiting macrophage infiltration and myofibroblast activation. Preferably, the bijective formulation exerts an anti-atherosclerosis effect by reducing oxidative stress, specifically by reducing MDA levels and restoring SOD and GSH-PX activity to normal levels. Preferably, the bijective exerts an anti-atherosclerosis effect by inhibiting inflammatory responses, specifically by reducing TNF-alpha levels, IL-1 beta levels. Preferably, the bivariate is capable of reducing intracellular lipid accumulation. Preferably, the dosage of the two refined formulas is 1.4g/kg-5.6g/kg. Use of a composition containing a bispermatid in the preparation of a medicament for the treatment of hyperhomocysteinemia-derived atherosclerosis. Compared with the prior art, the invention has the beneficial effects that: The bispermatid provided by the invention has the unique advantages of multiple targets, multiple ways and low toxic and side effects in treating hyperhomocysteinemia-derived atherosclerosis, and is a safe, effective and untoward effect-free medicament. According to the invention, an ApoE -/- mouse is taken AS an experimental object, a HHcy-AS composite model is established through 1.7% methionine diet induction, and the result shows that the bijective formula has obvious effects in the aspects of regulating Hcy metabolism, improving vascular endothelial functions, stabilizing arterial plaque and the like through multi-target and multi-path intervention on a pathological axis of Hcy-AS. Meanwhile, the bispermatid can improve the foaming of macrophages and VSMCs by regulating lipid accumulation, inhibiting inflammatory reaction, relieving oxidative stress injury, thereby playing a role in relieving Hhcy-derived atherosclerosis. Drawings Figure 1 is a diagram of a reepityriasis treatment capable of alleviating methionine diet induced ApoE -/- mice hyperhomocysteinemia and atherosclerosis. A. Body weight change curves of mice in each group (n=10), and comparison of food intake of mice (n=10). C. Blood Hcy level (n=6), d. Taking pictures of the mouse aorta, e. Staining with oil red O of the mouse aorta, f. Quantification of staining with oil red O of the mouse aorta (n=3). Note that, # represents P <0.05, # represents P <0.01, # represents P <0.001, # represents P <0.0001, as compared to the normal group. Compared to the model group, P <0.05, P